The Latest Cardiac and Vascular News
– Data to Be Presented at 2022 ACC Annual Meeting Demonstrate Valve Disease is More Common in Women in the U.S. – – Other Key Findings Suggest Tricuspid and Mitral Regurgitation Have Highest Prevalence Rates; Severe Mitral Regurgitation Diagnosed More Frequently in Centers Offering Percutaneous Mitral Therapies – ALISO VIEJO, Calif.–(BUSINESS […]
Results presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) Trial achieved primary reversal endpoint in older volunteers Bentracimab was well tolerated in the Phase 2b trial, with no drug-related serious adverse events or thrombotic events reported MALVERN, […]
GENT, Belgium–(BUSINESS WIRE)–FEops today announced that it received authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion (LAAo) with the Abbott’s Amplatzer™ Amulet™ and Boston Scientific’s Watchman FLX™ device*. FEops HEARTguide is a one-in-its-kind cloud-based procedure planning solution in the structural […]
– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease – by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association (JAMA) LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), […]
Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on guideline-recommended RAASi therapy Veltassa® prevented the recurrence of hyperkalemia events, potentially leading to better patient outcomes Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure […]
ACC.22: Late-breaking data show CoreValveTM and EvolutTM is the only platform to out-perform surgery in valve durability at five years Medtronic today unveiled new insights from a pooled analysis of high and intermediate risk patients from the CoreValve/Evolut program, showing a lower occurrence in structural valve deterioration (SVD) in patients […]
Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, Mass., April 1, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure […]
MIAMI, April 1, 2022 /PRNewswire/ — East End Medical, a private medical device company committed to improving catheter-based cardiac procedures, today announced the first commercial uses of its SafeCross™ Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The All-in-One system is designed to provide a predictable and safe solution for performing electrophysiology and […]
New collaboration to deliver information and resources targeted to the needs of physicians throughout Latin America NEW YORK, April 1, 2022 /PRNewswire/ — Medscape and the American College of Cardiology (ACC) today announced the launch of the Latin America Center for Cardiovascular Health Promotion (Spanish and Portuguese), a new collaboration that will deliver trusted scientific information and […]
HANGZHOU, China, March 31, 2022 /PRNewswire/ — On March 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as “Venus Medtech”), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its annual results for the year ended December 31, 2021. According to the financial report, Venus Medtech recorded RMB416 […]
